Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | STING1 | Q86WV6 | 5/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6188814 | 0.86 | MAPT (0.52) | MAPTRAB9AALDH1A1NPSR1LMNA | |
| SCHEMBL28556390 | 0.83 | GAA (0.47) | MAPTGAARAB9AALDH1A1LMNA | |
| SCHEMBL23115927 | 0.83 | AURKA (0.39) | MAPTGAARAB9AALDH1A1NPSR1 | |
| SCHEMBL5108674 | 0.83 | KDM4E (0.38) | MAPTGAARAB9AALDH1A1NPSR1 | |
| SCHEMBL22857792 | 0.82 | GAA (0.46) | MAPTGAARAB9AALDH1A1NPSR1 | |
| SCHEMBL30514592 | 0.82 | MAPT (0.49) | MAPTALDH1A1NPSR1LMNAPOLB | |
| SCHEMBL12688453 | 0.82 | GAA (0.46) | MAPTGAARAB9AALDH1A1NPSR1 | |
| SCHEMBL3817969 | 0.81 | CA12 (0.37) | MAPTGAARAB9AALDH1A1KDM4E | |
| SCHEMBL31094892 | 0.81 | KDM4E (0.38) | MAPTGAARAB9AALDH1A1NPSR1 | |
| SCHEMBL23115866 | 0.81 | CA12 (0.37) | MAPTGAARAB9AALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | MINDRANK AI LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-12497384-B2 | Aryl ether-substituted heterocyclic compounds as GLP1R agonists | MINDRANK AI LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| US-20250304553-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| US-20250282757-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2025-09-11 | — | — | US | disclosed |
| EP-4526298-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | F. Hoffmann-La Roche AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| CN-117242067-B | Novel aryl ether substituted heterocycles as GLP1R agonists | 杭州德睿智药科技有限公司 | 2025-03-25 | — | — | CN | disclosed |
| US-20250074913-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-06 | — | — | US | disclosed |
| CN-119212989-A | Pyrazole derivatives as STING agonists | 豪夫迈·罗氏有限公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-4353717-A1 | NOVEL ARYL ETHER SUBSTITUTED HETEROCYCLIC COMPOUND AS GLP1R AGONIST | Mindrank AI Ltd. (CN) | 2024-04-17 | — | — | EP | disclosed |
| WO-2024051700-A1 | NOVEL ARYL DEUTERATED BENZYL ETHER SUBSTITUTED HETEROCYCLIC COMPOUND AS GLP1R AGONIST | 德睿智药(苏州)新药研发有限公司 | 2024-03-14 | — | — | WO | disclosed |
| US-8455532-B2 | Pyrazolyl acrylonitrile compounds and uses thereof | SHENYANG RESEARCH INSTITUTE OF CHEMICAL INDUSTRY CO., LTD. (CN) | 2013-06-04 | — | — | US | disclosed |
| US-8455532-B2 | Pyrazolyl acrylonitrile compounds and uses thereof | SHENYANG RESEARCH INSTITUTE OF CHEMICAL INDUSTRY CO., LTD. (CN) | 2013-06-04 | — | — | US | disclosed |
| US-8455532-B2 | Pyrazolyl acrylonitrile compounds and uses thereof | SHENYANG RESEARCH INSTITUTE OF CHEMICAL INDUSTRY CO., LTD. (CN) | 2013-06-04 | — | — | US | disclosed |
| EP-2426110-A1 | PYRAZOLYL ACRYLONITRILE COMPOUNDS AND USES THEREOF | Sinochem Corporation (CN) | 2012-03-07 | — | — | EP | disclosed |
| EP-2426110-A1 | PYRAZOLYL ACRYLONITRILE COMPOUNDS AND USES THEREOF | Sinochem Corporation (CN) | 2012-03-07 | — | — | EP | disclosed |
| US-20120035236-A1 | Pyrazolyl Acrylonitrile Compounds and Uses Thereof | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2012-02-09 | — | — | US | disclosed |
| US-20120035236-A1 | Pyrazolyl Acrylonitrile Compounds and Uses Thereof | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2012-02-09 | — | — | US | disclosed |
| US-20120035236-A1 | Pyrazolyl Acrylonitrile Compounds and Uses Thereof | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2012-02-09 | — | — | US | disclosed |
| EP-0087780-B2 | Pyrazolesulfonylurea derivative, preparation thereof, herbicide containing said derivative as active ingredient and herbicidal method by use thereof | NISSAN CHEMICAL IND LTD (JP) | 1995-02-15 | — | — | EP | disclosed |
| US-4954164-A | Pyrazolesulfonylurea derivatives, preparation thereof, herbicide containing said derivative as active ingredient and herbicidal method by use thereof | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1990-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497384-B2 | Aryl ether-substituted heterocyclic compounds as GLP1R agonists | GLP1R, GIPR, GCGR | MAPT 3780/4885GAA 2562/4885RAB9A 592/4885 |
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | GLP1R, GIPR, GCGR | MAPT 4801/4885GAA 4195/4885RAB9A 1015/4885 |
| US-20250304553-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | GLP1R, GIPR, GCGR | MAPT 3889/4885GAA 2003/4885RAB9A 827/4885 |
| US-20250074913-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | STING1, CGAS, MAVS | MAPT 4128/4885GAA 3157/4885RAB9A 413/4885 |
| US-20250282757-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | GLP1R, GIPR, GCGR | MAPT 3591/4885GAA 2478/4885RAB9A 563/4885 |
| US-20120035236-A1 | Pyrazolyl Acrylonitrile Compounds and Uses Thereof | CBR3, C3AR1, C5 | MAPT 4805/4885GAA 4389/4885RAB9A 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.